Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-06-05
2007-06-05
Wehbe′, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C424S093100, C424S093700, C435S325000, C435S320100, C435S455000
Reexamination Certificate
active
09458610
ABSTRACT:
A method for the direct treatment towards the specific sites of a disease is disclosed. This method is based on the delivery of proteins by catheterization to discrete blood vessel segments using genetically modified or normal cells or other vector systems. Endothelial cells expressing recombinant therapeutic agent or diagnostic proteins are situated on the walls of the blood vessel or in the tissue perfused by the vessel in a patient. This technique, provides for the transfer of cells or vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of diseases.
REFERENCES:
patent: 4332893 (1982-06-01), Rosenberg
patent: 4353888 (1982-10-01), Sefton
patent: 4636195 (1987-01-01), Wolinsky
patent: 4824436 (1989-04-01), Wolinsky
patent: 4874746 (1989-10-01), Antoniades et al.
patent: 5087617 (1992-02-01), Smith
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5674722 (1997-10-01), Mulligan et al.
patent: 5707969 (1998-01-01), Nabel et al.
patent: 6001350 (1999-12-01), Mulligan et al.
patent: 6203991 (2001-03-01), Nabel et al.
patent: 0 273 085 (1986-12-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 90/11734 (1990-10-01), None
patent: WO 91/06309 (1991-05-01), None
Kaufman et. al.; XENOTRANSPLANTATION, 1995, Annu. Rev. Immunol13: 339-367.
Ledley; Nonviral Gene Therapy: The Promise of Gene as Pharmaceutical Products, 1995, Human Gene Therapy 6: 1129-1144.
Orkin et. al.; 1995; Reort and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.
J. Zwiebel et al., “High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral Vectors”,Science, vol. 243, pp. 220-222 (1989).
E. Nabel et al., “Recombinant Gene Expressionin VivoWithin Endothelial Cells of the Arterial Wall”,Science, vol. 244, pp. 1342-1344 (1989).
J. Wilson et al., “Implantation of Vascular Grafts Lined with Genetically Modified Endothelial Cells”,Science, vol. 244, pp. 1344-1346 (1989).
R. Selden et al, “Implantation of Genetically Engineered Fibroblasts into Mice: Implications for Gene Therapy”,Science, vol. 236 pp. 714-718, (1987).
H. Ogura et al., “Implantation of Genetically Manipulated Fibroblasts into Mice as Antitumor α-Interferon Therapy”,Cancer Research, vol. 50, pp. 5102-5106 (1990).
K. Broadley et al., “Transfection of Woundsin Vivowith Transforming Growth Factor-β1Accelerates Healing”,The FASEB Journal, vol. 5, No. 11 p. a539 (1991).
P. Felgner et al., “Lipofection: A Highly efficient, lipid-mediated DNA-transfection procedure”,Proc. Natl. Acad. Sci. USA, vol. 84, No. 21, pp. 7413-7417 (1987).
Nabel, Elizabeth G. et al.,Site-Specific Gene Expression In Vivo by Direct Gene Transfer Into the Arterial Wall, Science, pp. 1285-1288, vol. 249, Sep. 1990.
Nabel, Gary J. et al.,Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes, Proc. Natl. Acad. Sci. USA, vol. 93, p. 15388-15393, Dec. 1996.
Nabel, Gary, J. et al.,Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 11307-11311, Dec. 1993.
Nabel, Gary J.,Response to the Points to Consider for Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors, Human Gene Therapy, 3:705-711 (1992), Mary Ann Liebert, Inc., Publishers.
Ogura, Hiromi et al.,Implanation of Genetically Manipulated Fibroblasts into Mice as Antitumor α-Interferon Therapy, Cancer Research 50, 5102-5106, Aug. 15, 1990.
Plautz, Gregory E. et al.,Immunotherapy of malignancy by in vivo gene transfer into tumors, Proc. Natl. Acad. Sci. USA, vol. 90 4645-4649, May 1993.
Selden, Richard F. et al.,Implantation of Genetically Engineered Fibroblasts into Mice: Implications for Gene Therapy, Science, vol. 236, pp. 714-718, May 1987.
Tanaka, Kenichi et al.,Reversal of Oncogenesis by the Expression of a Major Histocompatibility Complex Class I Gene, Science, vol. 228, pp. 26-30, Apr. 1985.
Wang, Chen-Yen et al.,Highly Efficient DNA Delivery Mediated by pH-Sensitive Immunoliposomes, Biochemistry 1989, 28, 9508-9514.
Wilson, James M. et al.,Implantation of Vascular Grafts Lined with Genetically Modified Endothelial Cells, Science, vol. 244, pp. 1344-1346, Jun. 1989.
Wolff, Jon A. et al.,Transfer Into Mouse Muscle In Vivo, Science, vol. 247, Mar. 1990.
Zwiebel, James A. et al.,High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral Vectors, Science, vol. 243, pp. 220-222, Jan. 1989.
Broadley et al.,Federation of American Societies for Experimental Biology Journal, vol. 5, No. 4, pp. 539A, abstract 977, “Transfection of wounds in vivo with Transforming Growth Factor-B Accelerates Healing”, 1991.
Makrides, Savvas C., “Components of Vectors for Gene Transfer and Expression in Mammalian Cells.” 1999.Protein Expression and Purification, 17:183-202.
Verman, Inder M. and Nikunji Somia, “Gene therapy-promises, problems and prospects.” 1997.Nature, 389:239-242.
Inverardi, Luca and Camillo Ricordi, “Chapter 56: Cell Transplantation.” 1996.Transplantation Biology: Cellular and Molecular Aspects, pp. 679-687.
Peracchi, Alessio, “Prospects for antiviral ribozymes and deoxyribozymes.” 2004.Rev. Med. Virol., 14:47-64.
Agrawal, Sudhir and Ekambar R. Kandimalla, “Antisense therapeutics: is it as simple as complementary base recognition?” 2000.Molecular Medicine Today, 61:72-81.
Chirila, et al., “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.” 2002.Biomaterials, 23:321-42.
Branch, Andrea D., “A Good Antisense Molecule is Hard to Find.” 1998.Talking Point, TIBS 23:45-50.
Crooke, S.T. (ed.), “Antisense Research and Application.” 1998. Chapters 1 and 2, pp. 1-50.
Mulligan, Richard C.,The Basic Science of Gene Therapy, Science, vol. 260, May 14, 1993.
Hiroshi, Arai et al.,Gene transfer of Fas ligand induces tumor regression in vivo, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 13862-13867, Dec. 1997.
Hiroshi, Arai et al.,Inhibition of the alloantibody response by CD95 ligand, Nature Medicine, vol. 3, No. 8, Aug. 1997.
Brown, David,Gene Therapy ‘Oversold’ By Researchers, Journalists, The Washington Post, Dec. 8, 1995.
Bubenik, J. et al.,Local administration of cells containinig an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu
u mice, Immunology Letters, 19 (1988) 279-282.
Coghlan, Andy,Gene dream fades away, New Scientist, Nov. 25, 1995.
Felgner, Philip L. et al.,Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci, USA, vol. 84, pp. 7413-7417, Nov. 1987.
Nabel, Elizabeth G. et al.,Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall, Science, pp. 1342-1344, vol. 244, (1987).
Nabel, Gary J. et al.,Immunotherapy for Cancer by Direct Gene Transfer into Tumors, Human Gene Therapy, 5:57-77 (1994), Mary Ann Liebert, Inc., Publishers.
Nabel Elizabeth G.
Nabel Gary J.
The Regents of the University of Michigan
Wehbe′ Anne M.
LandOfFree
Treatment of diseases by site specific instillation of cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diseases by site specific instillation of cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diseases by site specific instillation of cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3838597